Accessibility Menu
Vanda Pharmaceuticals logo

Vanda Pharmaceuticals

(NASDAQ) VNDA

Current Price$5.89
Market Cap$353.00M
Since IPO (2006)-39%
5 Year-69%
1 Year+27%
1 Month-9%

Vanda Pharmaceuticals Financials at a Glance

Market Cap

$353.00M

Revenue (TTM)

$217.78M

Net Income (TTM)

-$239.55M

EPS (TTM)

-$4.05

P/E Ratio

-1.45

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$5.89

Volume

1,320,318.964

Open

$6.09

Previous Close

$5.87

Daily Range

$5.86 - $6.15

52-Week Range

$4.14 - $9.94

Estimated Earnings Date

Jul 29, 2026

VNDA: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vanda Pharmaceuticals

Industry

Biotechnology

Employees

533

CEO

Mihael Hristos Polymeropoulos, MD

Headquarters

Washington, DC 20037, US

VNDA Financials

Key Financial Metrics (TTM)

Gross Margin

92%

Operating Margin

-74%

Net Income Margin

-1%

Return on Equity

-60%

Return on Capital

-54%

Return on Assets

-55%

Earnings Yield

-68.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$353.00M

Shares Outstanding

60.14M

Volume

1.32M

Avg. Volume

1.30M

Financials (TTM)

Gross Profit

$203.06M

Operating Income

-$151.17M

EBITDA

-$126.73M

Operating Cash Flow

-$109.44M

Capital Expenditure

-$998.00K

Free Cash Flow

-$110.44M

Cash & ST Invst.

$263.85M

Total Debt

$12.62M

Vanda Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$51.72M

+3.4%

Gross Profit

$46.57M

+0.1%

Gross Margin

90.05%

N/A

Market Cap

$353.00M

N/A

Market Cap/Employee

$959.23K

N/A

Employees

368

N/A

Net Income

-$48.57M

-64.7%

EBITDA

-$44.90M

-44.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$202.31M

-40.7%

Total Debt

$13.07M

+11.3%

Accounts Receivable

$56.88M

+27.5%

Inventory

$1.70M

-11.6%

Long Term Debt

$7.05M

-4.1%

Short Term Debt

$6.02M

+37.1%

Return on Assets

-55.26%

N/A

Return on Invested Capital

-53.82%

N/A

Free Cash Flow

-$50.44M

-50.2%

Operating Cash Flow

-$50.22M

-51.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVIRAtea Pharmaceuticals, Inc.
$4.49+2.98%
TRDAEntrada Therapeutics, Inc.
$6.46+2.38%
ALLOAllogene Therapeutics, Inc.
$1.90+1.06%
VYGRVoyager Therapeutics, Inc.
$3.50+1.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98+0.02%
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%

Questions About VNDA

What is the current price of Vanda Pharmaceuticals?

Vanda Pharmaceuticals is trading at $5.87 per share.

What is the 52-week range for Vanda Pharmaceuticals?

Over the past 52 weeks, Vanda Pharmaceuticals has traded between $4.14 and $9.94.

How much debt does Vanda Pharmaceuticals have?

As of the most recent reporting period, Vanda Pharmaceuticals reported total debt of $13.07M.

How much cash does Vanda Pharmaceuticals have on hand?

Vanda Pharmaceuticals reported $54.03M in cash and cash equivalents in its most recent financial results.

What is Vanda Pharmaceuticals’s dividend yield?

Vanda Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.